#BREAKING: Johnson & Johnson Vaccine Approved In Zimbabwe

THE Medicines Control Authority of Zimbabwe (MCAZ), has approved the use of Johnson & Johnson vaccine in Zimbabwe in the management and prevention of COVID-19 infections. By Michael Gwarisa In an interview with HealthTimes, MCAZ Projects and Public Relations Officer, Mr Shingai Gwatidzo confirmed the development. MCAZ reviewed the technical documentation and clinical studies conducted and issued Emergency Use Authorisation for Ministry of Health and Child Care to consider adding to the vaccines for use in Zimbabwe,” said Mr Gwatidzo.  He added that the EUA is subject to a number…

Read More

Blood Clots, A Very Common Symptom In Persons With Severe COVID-19

THERE is a high probability of recording high blood clots cases in persons who are admitted in the Intensive Care Unit (ICU) and those with severe COVID-19 symptoms than in other groups, a top immunologist has said. By Michael Gwarisa Speaking during an informal meeting with Journalists recently, Dr Tinashe Gede said in as much as there has been concern over people developing blood clots from vaccines elsewhere in the world, the incidence of thrombosis or blood clots, COVID-19 had proved to be the most highly pro-thrombotic illness to have…

Read More

Rejecting Johnson & Johnson Vaccine Unscientific

THE decision by  the Zimbabwen government to reject the Johnson & Johnson vaccine on the grounds of safety and storage issues might not be the in the best interests of citizens and lacks the scientific evidence to back the reasons up, a leading local Immunologist has said. By Michael Gwarisa This comes after revelations that the  technology that was used to develop the Sputnik V vaccine that was recently donated by Russia to Zimbabwe is the same as the one that was used to develop the Johnson & Johnson Vaccines…

Read More

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, with co-primary endpoints of 14 days…

Read More

Top Global Pharmaceutical Firms Pledge Quality Healthcare For 1.7 Million Africans

JOHNSON &JOHNSON together with other major global pharmaceutical players have joined hands with Last Mile Health and Living Goods to increase access to healthcare to community based primary healthcare for nearly 1.7 million people in not less than six African countries. HealthTimes Repoter The other firms include  Lilly, Novartis (Novartis.com), Pfizer (Pfizer.com), GSK (GSK.com) and the Bill & Melinda Gates Foundation (GatesFoundation.org) and the pledge is part of their shared commitment to accelerate universal health coverage. The Health Worker Training Initiative is a three-year investment, generously matched by The Audacious…

Read More